About the Journal
Aims and scope of journal
Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field.
Topics of particular interest include, but are not limited to, the following:
- Preclinical studies of new compounds, especially those that provide mechanistic insights
- Clinical trials and observations
- Reviews related to new drugs and current management of hematologic malignancies
- Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
The 2020 peer review performance metrics for Blood Cancer Journal are shown below:
Average time to decision without external review - 7 days
Average time to decision following external review - 52 days
Average time from submission to acceptance - 96 days
Average time from acceptance to publication - 13 days
Article page views - 565,712
Altmetric mentions - 1,642
The 2020 journal metrics* for Blood Cancer Journal are as follows:
2-year Impact Factor: 8.023
5-year Impact Factor: 7.607
Immediacy index: 1.354
Eigenfactor® score: 0.01040
Article influence score: 2.719
Rank: 25/244 Oncology, 6/76 Hematology
*2019 Journal Citation Reports® Science Edition (Clarivate Analytics, 2020)
Visit the Nature Research journals metrics page for a description of these metrics.
ISI Web of Science
The ISSN (online) number for Blood Cancer Journal is 2044-5385.